Tuesday, November 17, 2026

Hidden Side Effects of the GLP-1 Boom: Rare Risks to Body and Mind

As millions embrace blockbuster weight-loss and diabetes drugs, emerging data and new FDA warnings highlight uncommon but severe complications. Yes, it has the Shtarke Haskama of Oprah - but is it healthy?

By Ariana Eunjung Cha and Daniel Wu

Todd Engel runs his hand along the dining room table, pushed against a wall to help guide him through his Maryland home. On a good day, he can distinguish a shadow from the darkness.

Engel, 63, is legally blind. He can no longer drive and had to leave the job he loved operating heavy equipment. Most days, he stays home.

Four months after Engel started taking Ozempic to treat his diabetes, he woke one morning unable to see out of his right eye. His ophthalmologist told him the damage was permanent but couldn’t explain what caused it. Because no one suggested Ozempic might be involved, Engel kept taking the GLP-1 drug. Months later, he lost vision in his other eye.

“If anyone had told me there’s a possibility that this could happen, there is just no way that I would ever take that medication,” Engel said.

Engel is now among thousands of patients suing pharmaceutical giants Novo Nordisk and Eli Lilly, alleging they were not adequately warned about the risks of their blockbuster GLP-1 medications.

For millions of patients, these drugs have proven safe and transformative, delivering substantial health benefits for obesity, diabetes, and heart disease. However, as adoption scales to tens of millions globally, rare and previously underappreciated complications are coming into focus. While severe gastrointestinal injuries account for the majority of legal claims, the list of potential side effects under medical scrutiny continues to expand.

Whether Ozempic directly caused Engel’s blindness remains disputed in court, and manufacturers maintain their products are safe.

  • Novo Nordisk: Spokesperson Liz Skrbkova stated that while the company recognizes the profound impact of vision loss and takes adverse event reports seriously, semaglutide (the active ingredient in Ozempic and Wegovy) has a "well-established safety profile" and the lawsuits are "without merit."

  • Eli Lilly: The maker of Mounjaro and Zepbound noted that it continuously monitors and reports safety data to the Food and Drug Administration (FDA), maintaining ongoing discussions with regulators regarding ophthalmic and gastrointestinal data.

As these lawsuits move through the courts, they raise a critical public health question: When millions of people are taking relatively new drugs, how much evidence of a rare but devastating risk is enough to require a formal warning?

Body SystemKey Concerns Under ScrutinyCurrent Scientific Consensus
Eyes & VisionNAION ("eye stroke"), diabetic retinopathyHigh alert: FDA recently mandated NAION warnings; overall retinopathy risk appears unchanged in recent large reviews.
GastrointestinalGastroparesis (stomach paralysis), gallstones, pancreatitisMixed: Clearer link to gallstones; gastroparesis signals remain rare; bowel obstruction alarms have weakened.
Nutritional & BoneVitamin/mineral deficiencies, hair loss, osteoporosisGrowing concern: Linked to rapid weight loss and reduced caloric intake; higher fracture rates seen in older adults.
ReproductiveMenstrual irregularities, unexpected pregnancies, libido shiftsInconclusive: Disproportionate bleeding reports exist, alongside improved ovulation in women with metabolic conditions.
PsychiatricAnhedonia ("meh" mood), anxiety, disordered eatingUnclear: Anecdotal reports of mood shifts contrast with large observational studies showing lower depression/self-harm risks.
CancerThyroid C-cell tumors (boxed warning)Reassuring: Rodent tumor risks have not translated to humans in large trial analyses; potential protective effects under study.

Eyes and Vision

While broad eye-safety problems have not materialized—a 2026 study of 5.5 million people actually associated GLP-1 use with a lower incidence of macular degeneration—specific, severe conditions remain a major focus for regulators.

  • NAION ("Eye Stroke"): Nonarteritic anterior ischemic optic neuropathy occurs when blood flow to the optic nerve is disrupted, causing sudden vision loss. A March study of over 102,000 U.S. veterans found that semaglutide users faced roughly twice the risk of NAION compared to patients starting other common diabetes drugs. Following similar moves by regulators in Europe, Britain, Canada, and Australia, the FDA recently ordered GLP-1 makers to add new safety warnings regarding a potentially higher risk of NAION. (A separate April study of 90,000 Novo Nordisk clinical trial participants found no association).

  • Diabetic Retinopathy: Although early trials raised alarms that rapid blood-sugar improvements might worsen retinal blood vessel damage—a risk still listed on semaglutide labels—a 2025 JAMA Ophthalmology review of 78 trials found no overall increased risk.

Gastrointestinal and Digestive

Novo’s Ozempic and Wegovy contain semaglutide, which mimics a natural gut hormone that regulates blood sugar and signals fullness. Lilly’s Mounjaro and Zepbound use tirzepatide, targeting both GLP-1 and GIP hormone pathways.

While common side effects like nausea, diarrhea, and constipation are well-documented and usually temporary, the drugs' profound slowing of digestion has prompted closer looks at severe injuries:

  • Digestive Tract Motility: Gastroparesis, a condition where the stomach empties abnormally slowly, has been linked to GLP-1s in published case reviews, though researchers note larger studies are needed to determine true incidence rates. Conversely, early alarms regarding bowel obstruction were largely alleviated by a subsequent large-scale analysis showing no increased risk overall.

  • Gallbladder and Pancreas: Gallstones represent one of the clearest documented risks; a review of 55 trials (106,395 patients) found a 46 percent relative increase, though the absolute risk remained small. Pancreatitis remains on U.S. warning labels, even as clinical trials have yet to establish a definitive causal spike.

Nutritional and Physical Health

Physicians increasingly warn that rapid weight loss and sharply curtailed appetites can leave patients vulnerable to malnutrition.

  • Deficiencies and Hair Loss: A 2025 review highlighted multiple reports of GLP-1 users developing deficiencies in vitamin D, iron, and calcium. Additionally, a July University of Pennsylvania study of 12,000 adults with Type 2 diabetes found a low but statistically increased risk of hair loss compared to other diabetes medications.

  • Bone Density and Fractures: A study of more than 46,000 older adults with diabetes revealed that GLP-1 users had an 11 percent higher risk of fragility fractures. John Gabriel Horneff, an associate professor of clinical orthopedic surgery at the University of Pennsylvania, noted that poor nutritional intake during rapid weight loss likely plays a role. "Patients think about this as a weight-loss drug, but you don’t just impact fat tissue," Horneff said. "You impact muscle mass and certainly bone … as well."

Reproductive Health

Early media attention focused heavily on "Ozempic babies"—anecdotal reports of unexpected pregnancies—leaving scientists to untangle whether the drugs directly alter fertility or if weight loss simply restores ovulation and improves overall health.

  • Menstrual Changes: A July study in Obstetrics & Gynecology analyzing FDA adverse-event reports found disproportionate signals for heavy or intermenstrual bleeding and irregular cycles among semaglutide users. Yet another July study of 96 women with polyendocrine metabolic ovarian syndrome (PMOS) found that after six months on semaglutide, more than half of previously non-ovulating participants began ovulating again.

  • Sex Drive: A January review in Sexual Medicine Reviews found sharply divided patient experiences, with some reporting decreased libido or erectile dysfunction and others noting heightened desire—shifts that may stem from psychological or metabolic changes rather than direct pharmacological action.

Psychiatric and Behavioral

Online forums frequently feature users describing anhedonia—a blunted emotional state where life feels muted or "meh"—alongside anxiety and irritability. Clinical data, however, paints a complicated picture:

  • Mood and Self-Harm: A massive April study in The Lancet Psychiatry following 95,500 people with diabetes or obesity found that semaglutide users actually had a lower risk of worsening depression, anxiety, substance-use disorders, and self-harm, though the observational design cannot prove direct cause and effect.

  • Eating Disorders: Elizabeth Wassenaar, a regional medical director at Eating Recovery Center and Pathlight Mood & Anxiety Center, noted that while GLP-1s help quiet "food noise" for some, they can inadvertently trigger relapses in patients with a history of disordered eating. She emphasized the need for thorough mental health screening before prescribing.

Cancer

Both semaglutide and tirzepatide carry prominent boxed warnings regarding thyroid C-cell tumors, a precaution based on rodent studies. Human data has proven far more reassuring: a December 2025 analysis in Annals of Internal Medicine spanning 48 randomized trials (94,245 participants) found that GLP-1 drugs likely have little to no impact on the risk of thyroid, pancreatic, breast, or kidney cancers. Researchers are now actively investigating whether the medications might even help slow the growth of certain obesity-related cancers.

Living in the Dark

For Todd Engel, regulatory updates and statistical debates offer little comfort. Jonathan Orent of Motley Rice, Engel’s attorney and co-lead counsel in the NAION litigation, called the FDA’s new labeling mandate "an important step forward for patient safety," while arguing that the agency's delay left patients uninformed about a "life-altering catastrophe."

Meanwhile, Engel’s daily life is organized around counting steps, listening for auditory landmarks, and relying on bump dots placed on his microwave so he can feel the controls. At his 13-year-old grandson’s bar mitzvah, he sat in the front row, less than 15 feet away. Tears ran down his face—he could hear the ceremony, but he could not see it.

“I wake up in the dark,” he said, “and I go to sleep in the dark.”